Riskpilot← Back to searchSign inGet full accessANA2MI AS
ASActiveOrg 916518676Hauganveien 293, 3178 VåleWholesale of pharmaceutical and medical goods · NACE 4646Est. 20163 employees
Revenue 2025
NOK 15,1M
+19% vs 2024
EBITDA margin
15.4%
+513% vs 2024
Equity ratio
44.5%
Financial strength
Net profit 2025
NOK 1,9M
+385% vs 2024
| Revenue | NOK 15,1M | +19% |
| EBITDA | NOK 2,3M | +513% |
| Net profit | NOK 1,9M | +385% |
| Total assets | NOK 6,3M | +38% |
| Equity | NOK 2,8M | -6% |
| Employees | 3 | — |
Legal name
ANA2MI AS
Org number
916518676
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
6. januar 2016
Share capital
NOK 150 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Salg og konsulent tjenester innen medisinsk utstyr/forbruksmateriell til helseinstitusjoner, apotek og privatpersoner, samt produktutvikling innen medisinsk utstyr og forbruksmateriell.
Address
Hauganveien 293, 3178 Våle
Phone
+4748157449
Email
ordre@ana2mi.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 12 061 | 14 159 | 14 598 | 12 655 | 15 107 |
| Staff expenses | −1 655 | −2 728 | −3 037 | −3 699 | −2 907 |
| EBITDA | 3 160 | 2 459 | 2 300 | −565 | 2 332 |
| Depreciation & amort. | −38 | −43 | −41 | −14 | −0 |
| EBIT | 3 121 | 2 416 | 2 259 | −578 | 2 332 |
| Net financials | −26 | 28 | −52 | −101 | −15 |
| Profit before tax | 3 096 | 2 444 | 2 206 | −679 | 2 317 |
| Tax | 690 | 540 | 500 | −0 | 381 |
| Net profit | 2 406 | 1 904 | 1 706 | −679 | 1 936 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 957 | 6 338 | 5 510 | 4 571 | 6 321 |
| Equity | 2 804 | 3 448 | 3 654 | 2 975 | 2 811 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 153 | 2 890 | 1 855 | 1 596 | 3 509 |
| Total debt | 2 153 | 2 890 | 1 855 | 1 596 | 3 509 |
EBITDA margin
15.4%
This company
15.8%
Market median
+3% vs market
20212025
Equity ratio
44.5%
This company
38.2%
Market median
+16% vs market
20212025
Return on equity
68.9%
This company
18.4%
Market median
+274% vs market
20212025
Net profit margin
12.8%
This company
8.1%
Market median
+58% vs market
20212025
Asset turnover
2.39×
This company
1.12×
Market median
+113% vs market
20212025
Debt / equity
1.25×
This company
0.62×
Market median
-102% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JS Chief Executive Officer | Chief Executive Officer | 2016 |
| Former (1) | ||
JS Chief Executive Officer | Chief Executive Officer | 2016 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2021 | |
| Board of Directors | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ANA2MI AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jeanette Siltvedt | Chief Executive Officer | 0 companies |
| Jeanette Siltvedt Greger | Chief Executive Officer | 0 companies |
| Kari Nilsen | Chairman | 0 companies |
| Erik Vilhelm Forsberg | Board of Directors | 0 companies |